MAP2K7 and neoplasm: In the study presented here, decreased [18F]-FLT uptake following combination therapy preceded HCT116 tumour growth inhibition, suggesting that [18F]-FLT PET could be used as an early surrogate response biomarker for combined PI3K and MEK inhibitor treatment.